Biological drugs in paediatric COVID-19 infection: what patients, which drug, how much and how long

Clin Exp Rheumatol. 2021 May-Jun;39(3):697-699. doi: 10.55563/clinexprheumatol/in7kn4. Epub 2021 Mar 25.

Authors

Maria Vincenza Mastrolia¹, Ilaria Maccora¹, Edoardo Marrani¹, Ilaria Pagnini¹, Gabriele Simonini²

Affiliations

¹ Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy.
² Neurofarba Department, University of Florence, Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy. [email protected].

PMID: 33769268
DOI: 10.55563/clinexprheumatol/in7kn4

No abstract available

Publication types

Letter

MeSH terms

Biological Products*
COVID-19*
Child
Humans
Pharmaceutical Preparations*
SARS-CoV-2

Substances

Biological Products
Pharmaceutical Preparations